Andreas Herrmann

Andreas Herrmann has a diverse work experience in the biopharmaceutical industry. Andreas currently serves as the Chief Executive Officer of Corat Therapeutics, a biotech company focused on developing biopharmaceutical drugs for the treatment of Covid-19. Previously, Herrmann was the CEO of Valerius Biopharma AG, where they specialized in the development of specialty biosimilars. Andreas also held the position of CEO at Baliopharm AG, where they developed innovative biopharmaceuticals for autoimmune diseases and tumor indications. Herrmann also worked as the Managing Director at Probiocon GmbH, a consulting company for pharmaceutical companies, and as the CEO at Alvotech ehf / Alvotech Swiss, a leading company in the development of biosimilar compounds. Prior to that, they were the CEO of Celonic AG, a contract manufacturing organization in the biopharmaceutical industry. Andreas also held roles at Cardion AG, Cardiogene AG, and the University of Duesseldorf.

Andreas Herrmann earned their university entrance diploma in Finance, General from Georg Büchner Gymnasium in Köln-Weiden from 1973 to 1982. Andreas then pursued a PhD in Biochemistry at the University of Cologne from 1984 to 1994.